AKT1 and metabolic dysfunction-associated steatohepatitis: In our comparison of PT-NASH to NT-NASH, we identified dysregulation of the PI3K-Akt signaling pathway, which has been associated with metabolic dysfunction, including obesity, metabolic syndrome, and NAFLD (16).